"In February 2020, Apabetalone became the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a major cardiovascular indication, to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy."
Recent Posts
See AllRakovina highlighted the development of its kt-3000 drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tutors..
FDA has granted the request for a meeting to review the clinical trial protocol for its Phase 3 study in high-risk COVID-19 outpatients.
The CPP brings together businesses, policy makers, and NGOs to work together and create a national solution to plastic waste and pollution..